Last Seen Blogs
cutterdifferentwastelandque-blog
Untitled
codekulcom-blog
Untitled
hirefullstack
Hire Full Stack Developer India
mrduckstepsout
Mr Duck Steps Out
prairiechzhead
Little Cheesehead on the Prairie
Text
Tasigna 150mg - Anticancer drugs | view uses, side effects and price | MHP
tasigna 150mg | tasigna 150mg tablet | tasigna 150mg tablet price in india
NILOTINIB 150MG
DESCRIPTION
Nilotinib sold under the brand name tasigna 150mg tablet and its belongs to targeted cancer cells tasigna 150mg tablet is anticancer drugs, which prohibits development of the cancer cells.
tasigna 150mg is a prescription medicine, which sold under the supervision of medical oncologist. tasigna 150mg is also belongs to the class of kinase inhibitors.
tasigna 150mg tablet
TASIGNA INDICATION
tasigna 150mg tablet is mainly indicated in the conditions like; Chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included Imatinib in adult patients
MECHANISM OF ACTION
CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene tasigna 150mg tablet (nilotinib) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. tasigna 150mg tablet link to the ATP-bounding site of BCR-ABL protein tasigna 150mg inhibits proliferation of murine leukemic cell lines and human cell lines derived from patients with Philadelphia positive CML
PHARMACOKINETIC
ABSORPTION
The bioavailability of tasigna 150mg tablet are about 50% The time to high plasma concentration of tasigna 150mg tabletis occurred within 3 hours after administration.
EFFECT OF FOOD
The effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal when compared to fasted patient.
DISTRIBUTION
The binding of serum protein of the Tasigna 150mg is approximately 98% The drug nilotinib blood plasma ratio is 0.68
METABOLISM
tasigna 150mg tablet is metabolized through CYP3A4 mediated oxidation tasigna 150mg is the prime flowing component in the blood stream
ELIMINATION
The tasigna 150mg tablet half life period is approximately 17 hours
PRODUCT FDETAILS
Ingredients : Nilotinib
Strength : 150mg
Category : Anti-neoplastic drug
Price : tasigna 150mg tablet price in india
DOSAGE MANAGEMENT
The usual dose of Tasigna 150mg Tablet should be taken as two times in a day at time intervals of 12 hours. The tablet Tasigna 150mg administrated on an empty stomach. Food should not be taken for at least 1 hour after the dose is taken or 2 hours before the dose is taken
Tasigna 150mg capsules, should be dispersed in one teaspoon of applesauce for the patients, who are unable to taken through mouth Immediately within 15 minutes this mixture should be taken . concomitant use with hematopoietic growth factors such as erythropoietin or G-CSF is mandatory Also with hydroxyurea or anagrelide
DOSAGE IN ADULT PATIENTS WITH PHILADELPHIA POSITIVE CML-CP
The usual dose of the Tasigna 150mg tablet in this condition is 300mg should be given orally as twice daily.WITH RESISTANT OR INTOLERANT PHILADELPHIA POSITIVE CML-CP AND CML-AP
The recommended dose is 400mg should be administered as orally twice dailyIN PEDIATRICS
The usual dose for child 230mg/m2 should be administred orally twice daily The maximum dose of Tablet Tasigna 150mg is 400mg.
SIDE EFFECTS
TASIGNA SIDE EFFECTS
SKIN
Rash, Pruritus, alopecia, dry skin
GIT
Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
NERVE SYSTEM
Headache, dizziness
GENERAL
Fatigue, pyrexia, asthenia, peripheral edema, face edema
MUSCLE
Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
PULMONARY
Cough, oropharyngeal pain, dyspnea
INFECTIONS & INFESTATIONS
Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
EYE
Eyelid edema, periorbital edema
PSYCHIATRIC
Insomnia
VASCULAR
Hypertension
PREGNANCY & LACTATION
Pregnancy category: D Tasigna 150mg tablet avoid during pregnancy condition and women who become pregnant Tasigna 150mg not recommended in breastfeeding mothers
STORAGE
Stored at 68°F to 77°F (20°C to 25°C) keep the cartoon away from heat, moisture and light
MISSED DOSE
If patients missed to take the dose of Tasigna should be take within the time, or the missed dose should be skipped and follow the next dosing schedule.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO :+91-9940472902
WEBSITE : https://millionpharma.com/nilotinib-150mg.php
TRENDY KEYWORDS : tasigna 150mg | tasigna 150mg tablet | tasigna 150mg tablet price in india
0 notes
Text
Tasigna 200mg - Anticancer drugs | view uses, side effects and price | MHP
tasigna 200mg | tasigna 200mg tablet | tasigna 200mg tablet price in india
NILOTINIB 200MG
DESCRIPTION
Nilotinib( tasigna 200mg )sold under the brand name tasigna 200mg and its belongs to targeted cancer cells tasigna 200mg tablet is anticancer drugs, which prohibits development of the cancer cells.
tasigna 200mg tablet is a prescription medicine, which sold under the supervision of medical oncologist. tasigna 200mg tablet is also belongs to the class of kinase inhibitors.
TASIGNA INDICATION
tasigna 200mg tablet is mainly indicated in the conditions like; Chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included Imatinib in adult patients
MECHANISM OF ACTION
CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene Tasigna 200mg(nilotinib) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. tasigna 200mg link to the ATP-bounding site of BCR-ABL protein tasigna 200mg tablet inhibits proliferation of murine leukemic cell lines and human cell lines derived from patients with Philadelphia positive CML
PHARMACOKINETIC
ABSORPTION
The bioavailability of tasigna 200mg are about 50% The time to high plasma concentration of tasigna 200mg tablet is occurred within 3 hours after administration.
EFFECT OF FOOD
The effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal when compared to fasted patient tasigna 200mg tablet .
DISTRIBUTION
The binding of serum protein of the tasigna 200mg is approximately 98% The drug nilotinib blood plasma ratio is 0.68
METABOLISM
tasigna 200mg tablet is metabolized through CYP3A4 mediated oxidation tasigna 200mg t is the prime flowing component in the blood stream
ELIMINATION
The tasigna 200mg half life period is approximately 17 hours
PRODUCT DETAILS
Ingredients : Nilotinib
Strength : 200mg
Category : Anti-neoplastic drug
Price : tasigna 200mg tablet price in india
DOSAGE MANAGEMENT
The usual dose of tasigna 200mg tablet should be taken as two times in a day at time intervals of 12 hours. The tablet tasigna 200mg administrated on an empty stomach. Food should not be taken for at least 1 hour after the dose is taken or 2 hours before the dose is taken
tasigna 200mg capsules, should be dispersed in one teaspoon of applesauce for the patients, who are unable to taken through mouth Immediately within 15 minutes this mixture should be taken . concomitant use with hematopoietic growth factors such as erythropoietin or G-CSF is mandatory Also with hydroxyurea or anagrelide
SIDE EFFECTS
TASIGNA SIDE EFFECTS
SKIN
Rash, Pruritus, alopecia, dry skin
GIT
Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
NERVE SYSTEM
Headache, dizziness
GENERAL
Fatigue, pyrexia, asthenia, peripheral edema, face edema
MUSCLE
Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
PULMONARY
Cough, oropharyngeal pain, dyspnea
INFECTIONS & INFESTATIONS
Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
EYE
Eyelid edema, periorbital edema
PSYCHIATRIC
Insomnia
VASCULAR
Hypertension
DOSAGE IN ADULT PATIENTS WITH PHILADELPHIA POSITIVE CML-CP
The usual dose of the tasigna 200mg tablet in this condition is 300mg should be given orally as twice daily.
WITH RESISTANT OR INTOLERANT PHILADELPHIA POSITIVE CML-CP AND CML-AP
The recommended dose is 400mg should be administered as orally twice daily
IN PEDIATRICS
The usual dose for child 230mg/m2 should be administred orally twice daily The maximum dose of Tablet tasigna 200mg is 400mg.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO: +91-9940472902
WEBSITE: https://millionpharma.com/nilotinib-200mg.php
TRENDY KEYWORDS : tasigna 200mg | tasigna 200mg tablet | tasigna 200mg tablet price in india
0 notes
Text
Trasturel 150mg injection| Trastuzumab Uses & Side effects
trasturel 150mg | trasturel 150mg injection | trasturel 150mg injection price in india
TRASTUREL 150MG
DESCRIPTION
Trasturel 150mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology. Trasturel 150mg helps to decrease the rate of reactivation & mortality.
One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer. This factor is responsible for cell replication.
An FDA approved product Trasturel 150mg which is involved in breast cancer treatment.
Trasturel 150mg injection vial with 858mg of lyophilized powder containing 150mg of Trastuzumab
trasturel 150mg injection
INDCATION
The drug Trasturel 150mg is used for the treatment of Supportive treatment for breast cancerThe drug Trasturel 150mg is used for the treatment of Advanced breast cancer
The drug Trasturel 150mg injection is used for the treatment of Advanced gastric cancer
MECHANISM OF ACTION
Trasturel 150mg injection is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2.
HER2 pathway is specific for cell proliferation, joining of Transtuzumab to the site of HER2 causes prevention of this activity.
This joining leads to antibody mediated and leads to HER2 positive cells break down.
Trasturel 150mg is an intermediary of anti-body dependent cellular cytotoxicity.
PRODUCT DETAILS
Brand : Trasturel
Ingredients : Trastuzumab
Strength : 150mg
Manufactured : Reliance Life sciences
Package : 1 injection in 1 vial
Price : trasturel 150mg injection price in india
PHARMACOKINETICS
DISTRIBUTION
Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab emtansine.
METABOLISM
As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes.
EXCRETION
Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx. 4 days as trastuzumab emtansine.
Elimination of drug includes clearance of IgG through the reticuloendothelial system.
DOSAGE MANAGEMENT
Adjuvant regimen for HER2 over expressing Breast cancer:52 weeks of treatment total schedules as follows:
• Combination With paclitaxel or docetaxel, over a 90 minutes, 4mg/kg IV then over 30 minutes, 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel for 18 weeks one week following the last weekly dose.
• Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
Esophageal carcinoma or gastric cancer for adult dose:
• 8mg/kg IV over 90 minutes as initial dose
• 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose
• Duration of therapy for initial and maintenance dose until disease progression.
Breast cancer Metastatic HER2-Overexpressing:
• Over 90 minutes, 4mg/kg alone or with combination of paclitaxel in initial dose.
• Over 30 minutes, 2mg /kg once in a week for maintenance dose.
• Duration of therapy for initial and maintenance dose until disease progression.
Administration:
Trasturel is administer into vein through IV infusion over 90 minutes
Do not administer IV push or bolus.
Duration of Trasturel 150mg is administrated in once every week or every 3 weeks.
Before starting treatment, patients should undergo biopsy to check Trasturel 150mg injection is the right regimen the infusion solution should be compatible to polyvinyl chloride or polyethylene bags.
After dilution, the infusion bag should be stored at 2°C to 8°C for not more than 24 hours before use.
PRECAUTIONS
Embryo fetal damage;
Trasturel 150mg injection is contraindicated to pregnancy period.
Avoid becoming pregnancy during this therapy.
Use efficient contraceptives during treatment
Cardiomyopathy;
Trasturel 150mg receiving patients have increased risk of exposing to cardiac disorders.
Provide alternative therapy management
In serious condition, treatment should be discontinuing
Pulmonary toxicity;
Some serious fatal cases of pulmonary toxicity occur during Trasturel 150mg treatment.
Infusion reactions;
During Trasturel 150mg treatment some life-threatening infusion reactions are produced.
In serious infusion reactions, Stop the Trasturel 150mg treatment permanently.
Patient should be treated with premedication before starting the infusion to overcome the such problem,
During Trasturel 150mg treatment. Use with Caution.
Therapy induced neutropenia;
Higher incidence of neutropenia occurs during Trasturel 150mg treatment.
SIDE EFFECTS
The most common adverse effects;
Cardiomyopathy, Infusion reactions, Embryo fetal toxicity, Pulmonary toxicity, Chemotherapy induced neutropenia. The most common side effects;
Hypertension, Influenza, Dyspnea, URI, Rhinitis, Pharyngolaryngeal pain, Sinusitis, Epitasis, Pulmonary hypertension, Dizziness, Decrease LVEF, Palpitations, Arrhythmia, Cardiac failure, Cough, Interstitial pneumonitis, Diarrhea/constipation, Nausea, vomiting, Dyspepsia, Autoimmune thyroiditis, Neutropenia, Hypokalemia, Anemia, Thrombocytopenia, Febrile neutropenia, Renal failure, Abdominal pain, Arthralgia, Back pain, Bone pain, Headache, Paresthesia, Rash, Nail disorders, Pruritus, Pyrexia, Chills, Edema, Asthenia, Sudden death.
PREGNANCY:
Trasturel 150mg injection pregnancy category is D: Trasturel 150mg injection should not suggest during pregnancy condition.
LACTATION :
Breast feeding should not be recommended.
STORAGE :
Trasturel 150mg vials should be stored at refrigerator temperature of 2°C to 8°C
Keep the vial away from heat & light
After reconstitution, vial should be stored at 2°C to 8°C for 28 days.
Stored Trasturel 150mg diluted bag at 2°C to 8°C for 24 hours
MISSED DOSE:
If missed cycles of Trasturel 150mg treatment by one week or less, then the repeated maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedules: 6mg/kg) administer as soon as probably.
Until the next planned cycle, the patient does not take interval.
Consecutive Trasturel 150mg injection maintenance dose should be taken in 7 days or 21 days next confer to the weekly or 3 weekly schedules.
If patient missed to take Trasturel 150mg injection dose by higher than one week, then resume with re-storing dose of Trasturel 150mg such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should be administered over period of 90 minutes.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO: +91-9940472902
WEBSITE: https://millionpharma.com/trasturel-150mg.php
TRENDY KEYWORDS : trasturel 150mg | trasturel 150mg injection | trasturel 150mg injection price in india
0 notes
Text
Biceltis 440mg | Lapatinib | MHP
BICELTIS 440MG
biceltis 440mg | biceltis 440mg injection |biceltis 440mg injection price in india
DESCRIPTION
biceltis 440mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology.Biceltis 440mg helps to decrease the rate of reactivation & mortality.
One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer.
This factor is responsible for cell replication.
An FDA approved product biceltis 440mg injection which is involved in breast cancer treatment.
biceltis 440mg injection vial with 858mg of lyophilized powder containing 440mg of Trastuzumab.
biceltis 440mg injection
INDICATION
The drug biceltis 440mg injection is used for the treatment of Supportive treatment for breast cancer
The drug biceltis 440mg injection is used for the treatment of Advanced breast cancer
The drug biceltis 440mg injection is used for the treatment of Advanced gastric cancer.
MECHANISM OF ACTION
biceltis 440mg is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2.
HER2 pathway is specific for cell proliferation, joining of biceltis 440mg injection Transtuzumab to the site of HER2 causes prevention of this activity.
This joining leads to antibody mediated and leads to HER2 positive cells break down.
biceltis 440mg injection is a intermediary of anti-body dependent cellular cytotoxicity.
PRODUCT DETAILS
Brand :Biceltis
Ingredients : Lapatinib
Strength : 440mg
Manufactured : Emcure Pharmaceuticals
Package : 1 injection in 1 vial
Price : biceltis 440mg injection price in india
PHARMACOKINETICS
DISTRIBUTION
Volume of distribution: 44 mL/kg as trastuzumab ( biceltis 440mg injection ); 3.13 L as trastuzumab emtansine.
METABOLISM
As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes.
EXCRETION
Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx. 4 days as trastuzumab ( biceltis 440mg injection )emtansine. Elimination of drug includes clearance of IgG through the reticuloendothelial system.
DOSAGE MANAGEMENT
Adjuvant regimen for HER2 over expressing Breast cancer:
52 weeks of treatment total schedules as follows:
• biceltis 440mg injection Combination With paclitaxel or docetaxel, over a 90 minutes, 4mg/kg IV then over 30 minutes , 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel for 18 weeks one week following the last weekly dose.
• Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
Esophageal carcinoma or gastric cancer for adult dose:
• 8mg/kg IV over 90 minutes as initial dose
• 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose
• biceltis 440mg injection Duration of therapy for initial and maintenance dose until disease progression.
Breast cancer Metastatic HER2-Overexpressing:
• Over 90 minutes, 4mg/kg alone or with combination of paclitaxel in initial dose.
• Over 30 minutes, 2mg /kg once in a week for maintenance dose.
• Duration of therapy for initial and maintenance dose until disease progression.
Administration:
Biceltis 440mg is administer into vein through IV infusion over 90 minutes
Do not administer IV push or bolus.
Duration of B biceltis 440mg injection is administrated in once every week or every 3 weeks.
Before starting treatment, patients should undergo biopsy to check biceltis 440mg is the right regimenthe infusion solution should be compatible to polyvinyl chloride or polyethylene bags.
After dilution, the infusion bag should be stored at 2°C to 8°C for not more than 24 hours before use.
PRECAUTIONS
Embryo fetal damage;
biceltis 440mg is contraindicated to pregnancy period
Avoid becoming pregnancy during this therapy.
Use efficient contraceptives during treatment
Cardiomyopathy;
biceltis 440mg injection receiving patients have increased risk of exposing to cardiac disorders.
Provide alternative therapy management
In serious condition, treatment should be discontinuing
Pulmonary toxicity;
Some serious fatal cases of pulmonary toxicity occur during biceltis 440mg injection treatment.
Infusion reactions;
During biceltis 440mg injection treatment some life-threatening infusion reactions are produced.
In serious infusion reactions, Stop the biceltis 440mg treatment permanently.
Patient should be treated with premedication before starting the infusion to overcome the such problem,
During biceltis 440mg injection treatment. Use with Caution.
Therapy induced neutropenia;
Higher incidence of neutropenia occurs during biceltis 440mg injection treatment.
SIDE EFFECTS
The most common adverse effects;
Cardiomyopathy, Infusion reactions, Embryo fetal toxicity, Pulmonary toxicity, Chemotherapy induced neutropenia. The most common side effects;
Hypertension, Influenza, Dyspnea, URI, Rhinitis, Pharyngolaryngeal pain, Sinusitis, Epitasis, Pulmonary hypertension, Dizziness, Decrease LVEF, Palpitations, Arrhythmia, Cardiac failure, Cough, Interstitial pneumonitis, Diarrhea/constipation, Nausea, vomiting, Dyspepsia, Autoimmune thyroiditis, Neutropenia, Hypokalemia, Anemia, Thrombocytopenia, Febrile neutropenia, Renal failure, Abdominal pain, Arthralgia, Back pain, Bone pain, Headache, Paresthesia, Rash, Nail disorders, Pruritus, Pyrexia, Chills, Edema, Asthenia, Sudden death.
PREGNANCY:
biceltis 440mg pregnancy category is D: biceltis 440mg injection should not suggest during pregnancy condition.
LACTATION :
Breast feeding should not be recommended.
STORAGE :
biceltis 440mg vials should be stored at refrigerator temperature of 2°C to 8°C
Keep the vial away from heat & light
After reconstitution, vial should be stored at 2°C to 8°C for 28 days.
Stored biceltis 440mg injection diluted bag at 2°C to 8°C for 24 hours.
MISSED DOSE:
If missed cycles of biceltis 440mg treatment by one week or less, then the repeated maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedules: 6mg/kg) administer as soon as probably.Until the next planned cycle, the patient does not take interval.
Consecutive biceltis 440mg injection maintenance dose should be taken in 7 days or 21 days next confer to the weekly or 3 weekly schedules.
If patient missed to take biceltis 440mg injection dose by higher than one week, then resume with re-storing dose of B biceltis 440mg such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should be administered over period of 90 minutes.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO: +91-9940472902
WEBSITE: https://millionpharma.com/biceltis-440mg.php
TRENDY KEYWORDS : biceltis 440mg | biceltis 440mg injection |biceltis 440mg injection price in india
0 notes
Link
Beemainfratech are extremely immersed in manufacturing an inclusive range of Aluminium Scaffolding Dealers in Chennai, Tower Ladder, Step Ladder, Aluminium Ladder and FRP Ladder.Beema Infratech is one of the Scaffolding Dealers in Chennai.
0 notes
Text
Aluminium Ladder | Aluminium Scaffolding Dealers in Chennai
ALUMINIUM SCAFFOLDING DEALERS IN CHENNAI
Manufacturer of a wide range of products which include self support extension ladder, aluminum ladder, aluminum extension ladder, wall support extendable ladder, wall supporting straight ladder aluminium scaffolding dealers in chennai.
SELF SUPPORT EXTENSION LADDER
TABULAR LADDER
ALUMINIUM FOLDING LADDER
ALUMINIUM LADDER
ALUMINIUM EXTENSION LADDER
BEEMA INFRATECH ABOUTUS
CUSTOMER SATISFACTION
For the purpose of manufacturing the offered range, best quality materials are used. After designing and final finishing, the offered range of Aluminium Ladder and FRP Ladder undergoes various quality assurance procedures. For this, we have established an in-house quality testing unit. This unit is well-equipped and known for carrying out standardized quality testing procedures. Being a quality conscious and renowned name in this domain, we assure that the best quality of the offered range of Aluminium Ladder, FRP Ladder is maintained on our end and aluminium scaffolding dealers in chennai.
OUR INFRASTRUCTURE
Since the incorporation of our corporation, we have maintained a sound infrastructure base. The unit is well set with modern production machines and compulsory facilities that support us to manufacture the products in huge quantities. To have faultless control over business operations, we have partitioned this unit into several departments such as manufacturing department, quality department, warehousing department, packing department, R&D, and logistics department. These departments are managed by our extremely experts professionals.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO: +91 9381028255, +91 9489004466, +91 9489004433.
ADDRESS: №24, K. M. A. Garden, Industrial Estate Chinandimadam Kodungaiyur, Chennai- 600118, Tamil Nadu, India.
WEBSITE : https://beemainfratech.com
TRENDY KEYWORD : aluminium scaffolding dealers in chennai
0 notes
Text
Hertraz 440mg injection | Trastuzumab | MHP
hertraz 440mg injection | hertraz 440ng injection | hertraz 440mg injection price in india
HERTRAZ 440MG
DESCRIPTION
Hertraz 440mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology. Hertraz 440mg helps to decrease the rate of reactivation & mortality.
One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer. This factor is responsible for cell replication.
An FDA approved product Hertraz 440mg injection which is involved in breast cancer treatment.
Hertraz 440mg vial with 858mg of lyophilized powder containing 150mg of Trastuzumab
hertraz 440mg injection
breast cancer
INDICATION
The drug hertraz 440mg is used for the treatment of Supportive treatment for breast cancer
The drug hertraz 440mg injection is used for the treatment of Advanced breast cancer
The drug hertraz 440mg injection is used for the treatment of Advanced gastric cancer.
MECHANISM OF ACTION
hertraz 440mg injection is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2.
HER2 pathway is specific for cell proliferation, joining of ( hertraz 440mg injection ) Transtuzumab to the site of HER2 causes prevention of this activity.
This joining leads to antibody mediated and leads to HER2 positive cells break down.
hertraz 440mg injection is a intermediary of anti-body dependent cellular cytotoxicity.
PRODUCT DETAILS
Brand : hertraz
Ingredients : Trastuzumab
Strength : 440mg
Manufactured : Mylan Pharmaceuticals
Package : 1 injection in 1 vial
Price : hertraz 440mg injection price in india
PHARMACOKINETICS
DISTRIBUTION
Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab emtansine.
METABOLISM
As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes.
EXCRETION
hertraz 440mg injection Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx. 4 days as trastuzumab emtansine. Elimination of drug includes clearance of IgG through the reticuloendothelial system.
DOSAGE MANAGEMENT
Adjuvant regimen for HER2 over expressing Breast cancer:
52 weeks of treatment total schedules as follows: • Combination With paclitaxel or docetaxel, over 90 minutes, 4mg/kg IV then over 30 minutes, 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel for 18 weeks one week following the last weekly dose.
• Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
Esophageal carcinoma or gastric cancer for adult dose:
• 8mg/kg IV over 90 minutes as initial dose
• 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose
• Duration of therapy for initial and maintenance dose until disease progression.
Breast cancer Metastatic HER2-Overexpressing: • Over 90 minutes, 4mg/kg alone or with combination of paclitaxel in initial dose.
• Over 30 minutes, 2mg /kg once in a week for maintenance dose.
• Duration of therapy for initial and maintenance dose until disease progression.
Administration:
hertraz 440mg injection is administer into vein through IV infusion over 90 minutes
Do not administer IV push or bolus.
Duration of hertraz 440mg is administrated in once every week or every 3 weeks.
Before starting treatment, patients should undergo biopsy to check hertraz 440mg injection is the right regimen the infusion solution should be compatible to polyvinyl chloride or polyethylene bags.
After dilution, the infusion bag should be stored at 2°C to 8°C for not more than 24 hours before use.
PRECAUTIONS
Embryo fetal damage;
hertraz 440mg injection is contraindicated to pregnancy period.
Avoid becoming pregnancy during this therapy.
Use efficient contraceptives during treatment
Cardiomyopathy;
hertraz 440mg injection receiving patients have increased risk of exposing to cardiac disorders.
Provide alternative therapy management
In serious condition, treatment should be discontinuing
Pulmonary toxicity;
Some serious fatal cases of pulmonary toxicity occur during hertraz 440mg injection treatment.
Infusion reactions;
During hertraz 440mg injection treatment some life-threatening infusion reactions are produced.
In serious infusion reactions, Stop the hertraz 440mg injection treatment permanently.
Patient should be treated with premedication before starting the infusion to overcome the such problem,
During hertraz 440mg injection treatment. Use with Caution.
Therapy induced neutropenia;
Higher incidence of neutropenia occurs during hertraz 440mg injection treatment.
SIDE EFFECTS
The most common adverse effects;
hertraz 440mg injection Cardiomyopathy, Infusion reactions, Embryo fetal toxicity, Pulmonary toxicity, Chemotherapy induced neutropenia. The most common side effects;
Hypertension, Influenza, Dyspnea, URI, Rhinitis, Pharyngolaryngeal pain, Sinusitis, Epitasis, Pulmonary hypertension, Dizziness, Decrease LVEF, Palpitations, Arrhythmia, Cardiac failure, Cough, Interstitial pneumonitis, Diarrhea/constipation, Nausea, vomiting, Dyspepsia, Autoimmune thyroiditis, Neutropenia, Hypokalemia, Anemia, Thrombocytopenia, Febrile neutropenia, Renal failure, Abdominal pain, Arthralgia, Back pain, Bone pain, Headache, Paresthesia, Rash, Nail disorders, Pruritus, Pyrexia, Chills, Edema, Asthenia, Sudden death.
PREGNANCY:
hertraz 440mg injection pregnancy category is D: hertraz 440mg injection should not suggest during pregnancy condition.
LACTATION :
Breast feeding should not be recommended.
STORAGE :
hertraz 440mg injection vials should be stored at refrigerator temperature of 2°C to 8°C
Keep the vial away from heat & light
After reconstitution, vial should be stored at 2°C to 8°C for 28 days.
Stored hertraz 440mg injection diluted bag at 2°C to 8°C for 24 hours.
MISSED DOSE:
If missed cycles of hertraz 440mg treatment by one week or less, then the repeated maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedules: 6mg/kg) administer as soon as probably.
Until the next planned cycle, the patient does not take interval.
Consecutive hertraz 440mg injection maintenance dose should be taken in 7 days or 21 days next confer to the weekly or 3 weekly schedules.
If patient missed to take hertraz 440mg dose by higher than one week, then resume with re-storing dose of hertraz 440mg injection such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should be administered over period of 90 minutes.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO: +91-9940472902
WEBSITE: https://millionpharma.com/hertraz-440mg.php
TRENDY KEYWORDS : hertraz 440mg injection | hertraz 440ng injection | hertraz 440mg injection price in india
0 notes
Text
Alecensa 150mg | Alectinib | MHP
alecensa 150mg capsule | alecensa 150mg | alecensa 15omg capsule price in india
ALECENSA 150MG
DESCRIPTION
alecensa 150mg capsule consist of second-generation anaplastic lymphoma kinase (ALK) inhibitor authorized by the US Food and Drug Administration to cure crizotinib-refractory non-small cell lung cancer
alecensa 150mg capsule inhibits the developments of cancer cells which are then damaged by the body
alecensa 150mg which is used as prescription drug under the supervision of medical oncologist.
alecensa 150mg capsule
INDICATION
alecensa 150mg capsule is prescribed for the therapy in patientsaffected by anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
MECHANISM OF ACTION
alecensa 150mg capsule ALK is a family of proteins known as receptor tyrosine kinases (RTKs), which are included in the growth of cells and the development of new blood vessels which supply them. In patients with ALK-positive NSCLC, an abnormal form of ALK is formedwhichencourage the cancer cells to multiply and grow in an uncontrolled fashion. The active substance in Alectinib, is an ALK inhibitor and acts by stopping the action of ALK, thereby decreasing the growth and spread of the cancer.
PRODUCT DETAILS
Brand :Alecensa
Ingredients : Alectinib
Strength : 150mg
Manufactured : Genentech, Inc
Package : 240 capsules
Price :alecensa 15omg capsule price in india
ADME
Highplasma concentration 4 hours and bioavailability of alecensa 150mg capsule 37%
Humanplasma proteins binding is 99%
The drug alecensa 150mg capsule has Metabolized by CYP3A4 to its major active metabolite M4, the main circulating moieties in plasma, total radioactivity 76% constituting.
In oral administration, radioactivity 98% was eliminated in feces. dose was excreted in the feces unchanged ( alecensa 150mg capsule )Alectinib is 84%. Half-life is 33 hours
DOSAGE MANAGEMENT
Non- Small Cell Lung Cancer :
The prescribed dose is 600mg PO BID until disease progression or unacceptable
Renal impairment patient’s prescribed dose is 450mg orally twice in a day
Alecensa 150mg capsule is administrated with food.
PRECAUTIONS
When administered to pregnant women Embryo-fetal toxicity resulted: Based on data from animal studies and its mechanism of action, Alecensa 150mg can cause fetal harm.
While on treatment with Alecensa will causes Symptomatic bradycardia; control heart rate and blood pressure regularly.
alecensa 150mg capsule treatment may causes severe muscle pain and elevated CPK resulted; advise patients to report any unexplained muscle pain, tenderness, or weakness;
During alecensa 150mg capsule treatment Renal impairment occurred; incidence of Grade ≥3 renal impairment was 1.7%, of which 0.5% were fatal events.
SIDE EFFECTS
Alecensa 150mg capsule has some side effects while administrating certain condition as follows :
COMMON SIDE EFFECTS :
Muscle pain, Bradycardia, Tiredness, Constipation, Anemia , Hepatotoxicity, Trouble breathing, Shortness of breath , Cough, Fever .
Serious side effects :
Anemia, Fatigue, Liver problems, Hyperglycaemia, Constipation, Hypercalcemia, Muscle and bone pain, Edema, Low potassium.
PREGNANCY
Pregnancy Category D: Based on studies of animal and pharmacological action, alecensa 150mg will cause fetal harm when given to pregnant women
While on treatment with Alecensa 150mg tell the female not to become pregnant
LACTATION
While on treatment with alecensa 150mg capsule , discuss with the women not to breastfed to infants
STORAGE
Store at below 30°C
Keep the drug in its original container.
MISSED DOSE
If the patient missed to take a dose, then should not to take an extra dose, but before taking the next dose, have the missed dose at the regular time, leave the missed dose. Consult the doctor
CONTACT DETAILS
EMAIL :[email protected]
PHONE NO :+91-9940472902
WEBSITE :https://millionpharma.com/alecensa-150mg.php
0 notes
Text
Best Web Portal Development Services in Chennai - Apple Infoway Pvt Ltd
Apple Infoway Pvt Ltd is a Best Web Portal Development Company & Expert in ERP Solutions , E commerce , Seo Services, Digital Marketing Training in Chennai @ +91-9380037777.
#web portal development services in chennai#web portal development company in chennai#apple infoway pvt ltd
0 notes
Text
Tafero Em Tablet(Treatment of HIV infection)
tafero em tablet|tafero em |tafero em tablet price in india
Drug profile :
tafero em tablet, It is a Combination of Tenofovir alafenamide and Emtriciabine.tafero em is a HIV Nucloside analog reverse transcriptase inhibitors.
tafero em tablet Used in the treatment of HIV-1 infection either alone or with other medications.
Uses Of Tafero Em Tablet:
tafero em tablet tablet is used in the treatment of hiv infection Either Alone Or With Other Medication.
• Swallow it as a whole. Do not chew, crush or break it. tafero em tabletis to be taken with food.tafero em tablet prevent hiv (virus) from multiplying,by reducing the amount of virus in your body. They also increase the cd4 cell (white blood cells that protect against infection) count in your blood.tafero em tablet related warningsalcoholinteraction with alcohol is unknown. Please consult your doctor.Pregnancyprobably safetafero em 200mg/25mg tablet is probably safe to use during pregnancy.
Mechanism of action:
tafero em tablet is a combination of two antiretroviral drugs, emcitarabine and tenofovir alafenamide which are mainly effective against RNA Viruses like Human immunodeficiency virus. tafero em Works By Inhibiting the action of the viral-enzyme reverse transcriptase. Which is neede by the virusto be able to replicate.
How To Take Medicine:
You Should To Take tafero em Tablets Swallowed Whole with a glass of water once a day with or without food .
Side Effect of Tafero Em:
• Headache
• Gastrointestinal upset
• Dizziness
• Fatigue
• Rash
• Difficulty In Sleeping
• Depression
Precautions:
• Do Not Take The Medicine if you are allergic to these medicines.
• Do Not Take The Medicine in pregnancy and breastfeeding
• In case of liver damage and kidney problem Avoid Taking tafero em tablet.
Storage
Store In Dry Place and in an air-tight container
• Keep medicines out of the reach of children.
CONTACT DEATAILS
Million Health Pharmaceuticals
Old.№131,New.№50,Pedariyar kovil street
Seven wells,Chennai-600001.Tamilnadu,India
Email : [email protected]
WEBSITE: https://pillsbag.com/products/tafero-em
TRENDY KEYWORDS: tafero em tablet|tafero em |tafero em tablet price in india
0 notes
Text
Myhep and Mydekla 12 Weeks Mylan Tablets Uses, MRP, Price india
myhep-mydekla | myhep-mydekla tablet | myhep-mydekla tablet price in india
Drug profile
myhep-mydekla tablets are anti-viral medication, containing two most predominant ingredients such as Sofosbuvir andDaclatasvir
myhep-mydekla tablets are single dose therapy, it is a prescription medicine used by the patients only under the knowledge of medical practitioner who are well practiced
myhep-mydekla tablet is not used alone, for better action it should be combined with Myhep tablet.
In some condition myhep-mydekla is combined with ribavirin, an anti-viral medicine used in decompensated (Child Pugh B or C) cirrhosis
Brand name: Myhep Mydekla
Active components: Myhep-Sofosbuvir, Mydekla-Daclatasvir
Strength of the components: 400mg & 60mg respectively
Mfg: Mylan pharmaceuticals
Package: 28 tablets in a container
Category: Anti-viral drug
price : Myhep-Mydekla price in india
Prescribing information for Myhep Mydekla
The main indication of myhep-mydekla tablet is;
This combination tablets are used to treat the chronic hepatitis C viral infection caused by genotype I or III
The major limitation occurred while using myhep-mydekla tablet tablets are reduction of constant virological response rate in hepatitis C genotype I or III infected patients.
Mechanism of Myhep Mydekla
The activity of myhep-mydekla tablet are occurred by involving in some mechanism;
Myhep:
Myhep containing sofosbuvir has anti-hepaciviral activity, which is directly acting drug exhibits its action by prohibiting NS5B RNA reliant RNA polymerase enzyme; essential for hepatitis viral multiplication.
Sofosbuvir is metabolized to form uridine triphosphate, an essential active metabolite which exposes an anti-viral activity.
The infusion of this active metabolite into hepatitis viral RNA with the help of NS5B polymerase and causes viral chain discontinuation
Mydekla:
Mydekla containing Daclatasvir expels anti-viral activity by prohibiting NS5A protein which is needful in viral production and virion accumulation
Absorption
The peak plasma concentration of Mydekla tablets occurs within the range of 2 hours
The absolute bioavailability of Mydekla is 67%
The peak plasma concentration of Myhep tablets occurs within the range of 0.5 to 2 hours approximately.
The food will not creates any variation in absorption of myhep-mydekla tablet , may be taken with or without food
Distribution
The volume of distribution in Mydekla tablet is 47L
The human plasma protein bound with Mydekla tablet is nearly 99%
The blood to plasma ratio of Myhep is relatively 0.7
The human plasma protein bound with myhep-mydekla tablet occurs nearly 61 to 65%
Metabolism
Myhep is metabolized hepatically and formed as pharmacologically active metabolite uridine triphosphate, metabolism undergone with the help of cathepsin A or carboxylesterase 1
Mydekla metabolism occurred with the help of CYP3A4
Elimination
88% of Daclatasvir is excreted through feces 53% as an unchanged form, 6.6% excreted through urine.
The terminal half life period of Daclatasvir is occurred at 12 to 15 hours
Sofosbuvir metabolites are excreted through 80% in urine, 14% in feces & 2.5% in exhaled air
The terminal half life period of sofosbuvir is nearly 0.51 hours
How to take the Tablet Myhep Mydekla
myhep-mydekla tablet are administered with or without food, in the condition of hepatitis C viral infection originated by genotype I or III
myhep-mydekla tablet is single dose regimen
Dosage regimens
Generally Daclatasvir is not used alone, it is combined with sofosbuvir
The recommended dosage of myhep-mydekla tablet is one tablet should be taken as a single dose
If sofosbuvir is discontinued, Daclatasvir also get stopped
Genotype I:
Patient suffered without cirrhosis or with compensated cirrhosis:
The recommended dosage of myhep-mydekla tablet is one tablet should be taken as a single dose with or without food
In decompensated cirrhosis patients:
myhep-mydekla tablet should be combined with ribavirin as a single dose
Genotype III:
Patient suffered without cirrhosis or with compensated cirrhosis:
The recommended dosage of myhep-mydekla tablet is one tablet should be taken as a single dose with or without food
In decompensated cirrhosis patients:
myhep-mydekla tablet should be combined with ribavirin as a single dose
The dosage of ribavirin;
On basis of body weight & hemoglobin level of patients, dose can be calculated.
Less than 75kg: 1000mg of ribavirin; in genotype I or III 600mg of ribavirin as an initial dose and followed as 1000mg/per
At least 75 kg: in decompensated cirrhosis 1200mg of ribavirin given as twice daily
The safety and efficacy of Mydekla has not been established <18 years
Myhep used in ≥12 years or weight of ≥35kg
Dosage adjustment in drug interaction;
If concurrent use with strong CYP3A inhibitors, the dosage of Mydekla is reduced to 30mg while co administration
Concurrent use with moderate CYP3A inducers, the dosage of Mydekla increased to 90mg
Concomitant use of Mydekla with CYP3A strong inducers should be avoided, it is contraindicated
myhep-mydekla tablet caused side effects
The most common side effects occurred during the therapy;
Headache
Fatigue
Nausea
Diarrhea
Elevation of lipase
Cardiac problems like symptomatic bradycardia
Insomnia
Pruritus
Myalgia
Pancytopenia
Asthenia
Rashes
Loss of appetite
Irritability
Neutropenia
Anemia
Chills
Influenza like symptoms
Pyrexia
Drug interaction
While combining myhep-mydekla tablet with strong CYP3A inducers causes loss of virological reaction rate of both products
myhep-mydekla tablet with HMG CoA reductase inhibitors, this combination leads to cause increasing the exposure of these drugs (statins)
CYP3A strong inducers like st Johns wort, rifampin, phenytoin or carbamazepine
If Myhep combines with P-gp or BCRP inhibitors leads to cause elevation of sofosbuvir plasma concentration
myhep-mydekla tablet concomitant with amiodarone causes serious symptomatic bradycardia
myhep-mydekla tablet tablets concomitant with anti-convulsants, anti-mycobacterials or herbal products like st Johns wort causes decrease in effect of concentration of myhep-mydekla tablet
Food drug interaction
myhep-mydekla tablet with herbal product like st. Johns wort causes decreasing the therapeutic effect of myhep-mydekla tablet
No food drug interaction occurs
While using myhep-mydekla tablet , caution should be taken
Diet should be discussed with consultant
Possible contraindications
Some contraindications occurs while using myhep-mydekla tablet tablets
In decompensated cirrhosis, combines with ribavirin contraindicated in pregnancy condition
Some anaphylactic reaction occurs if patients are contraindicated to the components present in myhep-mydekla tablet
Safety measures
myhep-mydekla tablet causes serious bradycardia while concurrent use with amiodarone, to prevent this condition some alternative medicine is given or discontinue the amiodarone if possible. Counsel the patients about the exposure of bradycardia during the treatment
Using myhep-mydekla tablet with ribavirin, should not be recommended in pregnancy condition because of producing fetal damage due to ribavirin
While taking Myhep-Mydekla , with CYP3A strong inducers causes loss of therapeutic response of myhep-mydekla tablet . Avoid this concomitant to reduce the adverse effects
Pregnancy and lactation
myhep-mydekla tablet use in pregnancy, safe to use. The pregnancy category is B1
While combining with ribavirin, not recommended for pregnancy
Pregnancy category: X, causes fetal death
Breast feeding should not be recommended
Storage and handling
The storage condition of myhep-mydekla tablet should be stored at room temperature below 30oC (86oF) & 20oC and 25oC (68oF and 77oF) respectively
Container should be keep away from heat, light and moisture
Missed dose
Both myhep-mydekla tablet are single dose therapy, if patient fails to take the dose of these tablets, must consult the physician and take the dose within the time as per the instruction given by medical practitioner
Otherwise the missed dose should be skipped and follow the regular dosing schedule
Over dosage
The over dosage of myhep-mydekla tablet are occurred due to missed dose , if once over dosage occurs the patients must be monitored frequently for endorsement of toxicity and provide safety measures
Hemodialysis is a procedure used to eliminate the component from body, sofosbuvir removes with separation coefficient of 54% whereas Daclatasvir is problematic because nearly 99% of drug bounded to human plasma protein
CONTACT DETAILS
Million Health Pharmaceuticals
Old.№131,New.№50,Pedariyar kovil street
Seven wells,Chennai-600001.Tamilnadu,India
WEBSITE: https://pillsbag.com/products/myhep--mydekla-12-weeks
EMAIL: [email protected]
TRENDY KEYWORDS: myhep-mydekla |myhep-mydekla tablet |myhep-mydekla price in india
0 notes
Text
Jakavi 15mg tablets |Ruxolitinib | MHP
Jakavi 15mg | Jakavi 15mg tablet | Jakavi 15mg tablet price in india
JAKAVI 15MG
DESCRIPTION
Jakavi 15mg belongs to the classification of medications called anti-cancer drugs.
Jakavi 15mg tablet is a Janus kinase inhibitor with discrimination for subtypes JAK1 and JAK2 of this enzyme. Jakavi 15mg prohibits dysregulated JAK signaling along with myelofibrosis. This regimen is not prescribed for use in patients below 18 years of age.
Jakavi 15mg tablet is prescription drug provided under supervision of medical oncologist.
MECHANISM OF ACTION
Ruxolitinib is also known as targeted treatment which targets and joints to the tyrosine kinase receptors and prohibits Janus Associated Kinases (JAK1 and JAK2) which Intercede the signaling of several cytokines and growth factors which are important for hematopoiesis and immune function. By irrevocable to these receptors, Ruxolitinib(Jakavi 15mg tablet) stops important pathways which develop cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be analogue with dysregulated JAK1 and JAK2 signaling. Patients with MF who either carry the JAK2 V617 mutation or does not have the JAK2 V617F mutation may both respond to Ruxolitinib(Jakavi 15mg tablet).
PRODUCT DETAILS
Brand :Jakavi
Ingredients : Ruxolitinib
Strength : 15mg
Manufactured : Novartis Ltd
Package : Strips of 14 tablets
Price : Jakavi 15mg tablet price in india
ADME
Absorption:
Rapid absorption and not affected by food maximum plasma level is 1.5 hours.
Distribution:
Volume of distribution is 76.6 L plasma protein binding is 97%
Metabolism:
metabolized by CYP3A4
Elimination:
Excreted via urine 74% and unchanged drug is <1% and through urine 22%, <1 % as unchanged drug
DOSAGE MANAGEMENT
Myelofibrosis :
Starting recommended doses for myelofibrosis
If Platelet count >200 x10⁹/L the prescribed dose is 20 mg PO BID
If Platelet count 100–200 x10⁹/L the prescribed dose is 15 mg PO BID
If Platelet count 50 to <100 x10⁹/L the prescribed dose is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
Polycythemia Vera :
The prescribed dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2–4wk until doses are stabilized, and then as clinically used.
PRECAUTIONS
Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 15mg treatment. If PML is suspected, discontinue Jakavi 15mg tabletand evaluate.
Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have resulted in patients administrated with Jakavi 15mg. Do the periodic skin examinations.
Therapy with Jakavi 15mg can resulted in thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by decreasing the dose or temporarily prohibit Jakavi 15mg. Platelet transfusions may be needed.
Risk of infection occurs by delay initiate treatment with Jakavi 15mg tabletuntil active serious infection have resolved.
Tuberculosis infection has been resulted in patients administrating Jakavi 15mg. monitor patients getting Jakavi 15mg tablet for signs and symptoms of active tuberculosis and manage promptly.
SIDE EFFECTS
• Cholesterol level increased
• Dyspnea
• Nasopharyngitis
• Headache
• Constipation
• Decreased RBC
• Reduce in platelet counts
• Nausea & Vomiting
• Sleeplessness
• Liver enzymes increased
• Diarrhea
• bleeding
• Swelling
• Neutropenia
• Dizziness
PREGNANCY
The drug has no studies with the Jakavi 15mg use in pregnant women to inform drug-along with risks. Hence avoid becoming pregnancy duringJakavi 15mg treatment
LACTATION
Avoid breastfeeding to infants during treatment with Jakavi 15mg tablet.Excretion into human milk is unknown
STORAGE
Jakavi 15mg stored at 20°C to 25°C
Protect away from light and moisture
Dispense in its original container
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO:+91–9940472902
WEBSITE: https://millionpharma.com/jakavi-15mg.php
TRENDY KEYWORDS : Jakavi 15mg | Jakavi 15mg tablet | Jakavi 15mg tablet price in india
0 notes
Text
Ledihep Zydus Buy Online Tablets Uses, Side effects, Cost India
Ledihep | Ledihep tablet | Ledihep tablet price in india
Drug profile:
Ledihep tablets are an anti-viral agent.
Ledihep tablet which have procured by a patient only with the prescription
Ledihep tablet fixed-dose combination contains sofosbuvir and ledipasvir
Product details:
Trade name: Ledihep
Active components: sofosbuvir & ledipasvir
Strength of the components: 400mg & 90mg respectively
Mfg: Zydus hepatica
Package: 28 tablets in a container
Category: Anti-cancer agent.
Price : Ledihep tablet price in india
Ledihep Prescribing Information:
Ledihep is a very effective drug, involves in the treatment of chronic hepatitis C viral infection
Ledihep tablet is a single dose medicine, used alone or in combination with other anti-viral medicines in a chronic condition.
Ledihep, used by the patients having a valid prescription
Ledihep Mechanism of Action
Ledihep has two eminent compounds like;
Sofosbuvir & ledipasvir
Ledihep tablet is directly acting anti-viral drug, exhibits its activity by inhibiting the viral replication.
Ledipasvir: exhibits its action by intercedes with NS5A activity which is important for viral multiply, secretion, and colony of HCV virions. Due to the effect of ledipasvir, NS5A inhibitor causes eradicate viral growth.
Absorption:
The absorption of Ledihep tablet occurs rapidly, the peak plasma concentration of ledipasvir is 4 to 4.5 hours; sofosbuvir 0.8 to 1 hour and GS-331007 3.5 to 4 hours.
Distribution:
Ledihep should be administered with or without food; the human plasma protein bound of ledipasvir occurs as >99.8%; sofosbuvir 61 to 65%.
The metabolite of sofosbuvir GS-331007 has minimal plasma protein bounding capability.
Metabolism:
Ledihep tablet contains ledipasvir which is not metabolized hepatically and is excreted through feces as an unchanged form. Sofosbuvir metabolized to pharmacologically active form GS-461203.
Elimination:
Ledihep Excretion occurs through feces and urine
When to take the ledihep:
Ledihep tablet should be taken as a once a day, with or without the meal
Ledihep is a prescription medicine; care should be taken to avoid the self-medication problems
Ledihep tablet used either alone or with the combination.
Drug Interaction:
Ledihep concomitant with other drugs likes:
Ledihep tablet With antacids: like proton pump inhibitors, H2 receptor antagonist causes reduce effect of concentration ofledipasvir
Ledipasvir: Drug transporter P-gp inhibitors and breast cancer resistance protein inhibitor, while concomitant with Sofosbuvir and ledipasvir may causes increase the intestinal absorption of these substrates
Ledihep With anti-convulsants: reduce the effect of concentration of Sofosbuvir and ledipasvir
Ledihep With anti-mycobacterials: reduce the effect of concentration of Sofosbuvir and ledipasvir
Ledihep tablet with HMG CoA reductase: increase the effect of concentration of these lipid mimic drugs
Ledihep tablet With amiodarone: serious bradycardia occurs
Ledihep With digoxin: increase the effect of concentration of digoxin
Pregnancy and Lactation:
Ledihep with ribavirin pregnancy category: X
Ribavirin causes fetal death
Ledihep tablet pregnancy category: B1
Ledihep is safe to use in case of monotherapy (used alone)
Breastfeeding is not recommended for the patients who are getting ribavirin.
Storage and Handling:
Ledihep tablet container should be stored at room temperature below 30oC
The container should be kept away from moisture, heat, and light.
Missed Dose:
Ledihep tablet are prescription use, before taking the tablet patient must advise by a physician for avoiding self-medication.
If the patient fails to take the dose Ledihep, must consult with a medical practitioner and administered the missed dose as soon as possible within the time.
Overdosage:
The maximum dose of Ledihep Sofosbuvir and ledipasvir were 1200mg and 120mg twice daily for 10days.
No special antidote is recommended for overdosage of ledipasvir and Sofosbuvir
CONTACT DETAILS
Million Health Pharmaceuticals
Old.No.131,New.No.50,Pedariyar kovil street
Seven wells,Chennai-600001.Tamilnadu,India
email : [email protected]
WEBSITE : https://pillsbag.com/products/ledihep
0 notes
Text
Hertraz 150mg injection | Trastuzumab | MHP
Hertraz 150mg | Hertraz 150mg injection | Hertraz 150mg price in india
HERTRAZ 150MG
DESCRIPTION
Hertraz 150mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology. Hertraz 150mg helps to decrease the rate of reactivation & mortality.
One of the epidermal growth factor receptors is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer. This factor is responsible for cell replication.
An FDA approved product Hertraz 150mg which is involved in breast cancer treatment.
Hertraz 150mg vial with 858mg of lyophilized powder containing 150mg of Trastuzumab
INDICATION
The drug Hertraz 150mg is used for the treatment of Supportive treatment for breast cancer
The drug Hertraz 150mg is used for the treatment of Advanced breast cancer
The drug Hertraz 150mg is used for the treatment of Advanced gastric cancer.
MECHANISM OF ACTION
Hertraz 150mg injection is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2.
HER2 pathway is specific for cell proliferation, joining of Transtuzumab to the site of HER2 causes prevention of this activity.
This joining leads to antibody mediated and leads to HER2 positive cells break down.
Hertraz 150mg is a intermediary of anti-body dependent cellular cytotoxicity.
PRODUCT DETAILS
Brand : Hertraz
Ingredients : Trastuzumab
Strength : 150mg
Manufactured : Mylan Pharmaceuticals
Package : 1 injection in 1 vial
Price : Hertraz 150mg price in india
PHARMACOKINETICS
DISTRIBUTION
Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab emtansine.
METABOLISM
As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes.
EXCRETION
Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx. 4 days as trastuzumab emtansine. Elimination of drug includes clearance of IgG through the reticuloendothelial system.
DOSAGE MANAGEMENT
Adjuvant regimen for HER2 over expressing Breast cancer:
52 weeks of treatment total schedules as follows: • Combination With paclitaxel or docetaxel, over 90 minutes, 4mg/kg IV then over 30 minutes, 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel for 18 weeks one week following the last weekly dose.
• Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
Esophageal carcinoma or gastric cancer for adult dose:
• 8mg/kg IV over 90 minutes as initial dose
• 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose
• Duration of therapy for initial and maintenance dose until disease progression.
Breast cancer Metastatic HER2-Overexpressing: • Over 90 minutes, 4mg/kg alone or with combination of paclitaxel in initial dose.
• Over 30 minutes, 2mg /kg once in a week for maintenance dose.
• Duration of therapy for initial and maintenance dose until disease progression.
Administration:
Hertraz 150mg injection is administer into vein through IV infusion over 90 minutes
Do not administer IV push or bolus.
Duration of Hertraz 150mg is administrated in once every week or every 3 weeks.
Before starting treatment, patients should undergo biopsy to check Hertraz 150mg is the right regimen the infusion solution should be compatible to polyvinyl chloride or polyethylene bags.
After dilution, the infusion bag should be stored at 2°C to 8°C for not more than 24 hours before use.
PRECAUTIONS
Embryo fetal damage;
Hertraz 150mg is contraindicated to pregnancy period.
Avoid becoming pregnancy during this therapy.
Use efficient contraceptives during treatment
Cardiomyopathy;
Hertraz 150mg receiving patients have increased risk of exposing to cardiac disorders.
Provide alternative therapy management
In serious condition, treatment should be discontinuing
Pulmonary toxicity;
Some serious fatal cases of pulmonary toxicity occur during Hertraz 150mg treatment.
Infusion reactions;
During Hertraz 150mg injection treatment some life-threatening infusion reactions are produced.
In serious infusion reactions, Stop the Hertraz 150mg injection treatment permanently.
Patient should be treated with premedication before starting the infusion to overcome the such problem,
During Hertraz 150mg treatment. Use with Caution.
Therapy induced neutropenia;
Higher incidence of neutropenia occurs during Hertraz 150mg treatment.
SIDE EFFECTS
The most common adverse effects;
Cardiomyopathy, Infusion reactions, Embryo fetal toxicity, Pulmonary toxicity, Chemotherapy induced neutropenia. The most common side effects;
Hypertension, Influenza, Dyspnea, URI, Rhinitis, Pharyngolaryngeal pain, Sinusitis, Epitasis, Pulmonary hypertension, Dizziness, Decrease LVEF, Palpitations, Arrhythmia, Cardiac failure, Cough, Interstitial pneumonitis, Diarrhea/constipation, Nausea, vomiting, Dyspepsia, Autoimmune thyroiditis, Neutropenia, Hypokalemia, Anemia, Thrombocytopenia, Febrile neutropenia, Renal failure, Abdominal pain, Arthralgia, Back pain, Bone pain, Headache, Paresthesia, Rash, Nail disorders, Pruritus, Pyrexia, Chills, Edema, Asthenia, Sudden death.
PREGNANCY:
Hertraz 150mg injection pregnancy category is D: Hertraz 150mg injection should not suggest during pregnancy condition.
LACTATION :
Breast feeding should not be recommended.
STORAGE :
Hertraz 150mg vials should be stored at refrigerator temperature of 2°C to 8°C
Keep the vial away from heat & light
After reconstitution, vial should be stored at 2°C to 8°C for 28 days.
Stored Hertraz 150mg diluted bag at 2°C to 8°C for 24 hours.
MISSED DOSE:
If missed cycles of Hertraz 150mg injection treatment by one week or less, then the repeated maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedules: 6mg/kg) administer as soon as probably.
Until the next planned cycle, the patient does not take interval.
Consecutive Hertraz 150mg injection maintenance dose should be taken in 7 days or 21 days next confer to the weekly or 3 weekly schedules.
If patient missed to take Hertraz 150mg dose by higher than one week, then resume with re-storing dose of Hertraz 150mg injection such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should be administered over period of 90 minutes.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO:+91-9940472902
WEBSITE: https://millionpharma.com/hertraz-150mg.php
TRENDY KEYWORDS : Hertraz 150mg | Hertraz 150mg injection | Hertraz 150mg price in india
0 notes
Text
Jakavi 5mg tablets |Ruxolitinib | MHP
DESCRIPTION
Jakavi 5mg belongs to the classification of medications called anti-cancer drugs.
Jakavi 5mg tablet is a Janus kinase inhibitor with discrimination for subtypes JAK1 and JAK2 of this enzyme. Jakavi 5mg prohibits dysregulated JAK signaling along with myelofibrosis. This regimen is not prescribed for use in patients below 18 years of age.
Jakavi 5mg tablet is prescription drug provided under supervision of medical oncologist.
MECHANISM OF ACTION
Ruxolitinib( Jakavi 5mg )is also known as targeted treatment which targets and joints to the tyrosine kinase receptors and prohibits Janus Associated Kinases (JAK1 and JAK2) which Intercede the signaling of several cytokines and growth factors which are important for hematopoiesis and immune function. By irrevocable to these receptors, Ruxolitinib ( Jakavi 5mg )stops important pathways which develop cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be analogue with dysregulated JAK1 and JAK2 signaling. Patients with MF who either carry the JAK2 V617 mutation or does not have the JAK2 V617F mutation may both respond to Ruxolitinib.
ADME
Absorption:
Rapid absorption and not affected by food maximum plasma level is 1.5 hours.
Distribution:
Volume of distribution is 76.6 L plasma protein binding is 97%
Metabolism:
metabolized by CYP3A4
Elimination:
Excreted via urine 74% and unchanged drug is <1% and through urine 22%, <1 % as unchanged drug
PRODUCT DETAILS
Brand : Jakavi
Ingredients : Ruxolitinib
Strength : 5mg
Manufactured : Novartis Ltd
Package : 60 tablets
price : Jakavi 5mg price in india
DOSAGE MANAGEMENT
Myelofibrosis :
Starting recommended doses for myelofibrosis If Platelet count >200 x10^9/L the prescribed dose is 20 mg PO BID
If Platelet count 100-200 x10^9/L the prescribed dose is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the prescribed dose is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
Polycythemia Vera :
The prescribed dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.
PRECAUTIONS
Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 5mg treatment. If PML is suspected, discontinue Jakavi 5mg tablet and evaluate.
Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have resulted in patients administrated with Jakavi 5mg tablet. Do the periodic skin examinations.
Therapy with Jakavi 5mg can resulted in thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by decreasing the dose or temporarily prohibit Jakavi 5mg tablet. Platelet transfusions may be needed.
Risk of infection occurs by delay initiate treatment with Jakavi 5mg until active serious infection have resolved.
Tuberculosis infection has been resulted in patients administrating Jakavi 5mg tablet. monitor patients getting Jakavi 5mg for signs and symptoms of active tuberculosis and manage promptly.
SIDE EFFECTS
• Cholesterol level increased
• Dyspnea
• Nasopharyngitis
• Headache
• Constipation
• Decreased RBC
• Reduce in platelet counts
• Nausea & Vomiting
• Sleeplessness
• Liver enzymes increased
• Diarrhea
• bleeding
• Swelling
• Neutropenia
• Dizziness
CONTACT DETAILS:
EMAIL: [email protected]
PHONE NO: +91-9940472902
WEBSITE: https://millionpharma.com/ruxolitinib-5mg.php
TRENDY KEYWORDS: Jakavi 5mg tablet| Jakavi 5mg| Jakavi 5mg price in india
0 notes
Text
Best Web Portal Development Company in Chennai - Apple Infoway Pvt Ltd
WEB PORTAL DEVELOPMENT COMPANY IN CHENNAI
We maintain the lowest price-quality relation in our services in the market.
At Apple Infoway Pvt Ltd, we can ensure about helping you with the most effective solutions to accomplish your organizational goals. Web Portal Development Services In Chennai of Technologies are engrained with expertise and experience. Web portal development Services in chennai involves proficiency at many levels whether it is architectonics design, Database Planning, Graphical User Interface design, and coding. Web Portals are the best means of establishing your existence determinedly on the web.
Our Web portal development services in chennai supply you with down to earth solutions that can upgrade your business in line with your responsibility and aim. A portal well executed, creates a brand for its owner and develops into a gateway for the cyberspace users seamless.
Web portal development service in chennai revolves around developing all-inclusive web application connected with third-party(mediator) Application Programming Interface.The developers today use the Web strategies and quick fixes to develop web portal which includes bilateral tools like discussion forums, blogs, real-time chat, rating tools, polls, videos and so on.
WHY APPLE INFOWAY PVT LTD ?
“Unite this world into one”
Apple Infoway Pvt Ltd is an Information Technology Company in India establishing its platform’s on Internet-related services. Services like Business Process Management, Customer Relation Management, Enterprise Resource Planning, Digital Marketing, Job Portal, Web Design & Development, Search Engine Optimization, Social Media Optimization, Search Engine Marketing and Social Media Marketing.
Our Vision is to be present "high esteemed and excellence based software" provided to our clients.
At Apple Infoway Pvt Ltd , We mingle together with everyone for innovative ideas for each and every project and well, results are way beyond exception. The main motto of Apple Infoway Pvt Ltd is “Unite this world into one”. Apple Infoway Pvt Ltd was started in late 2016. Since then Apple Infoway Pvt Ltd have always been preaching employees about “union” which is and always has been Apple Infoway Pvt Ltd main secret on winning in projects handled by us. We have started our journey in late 2016 but we are popping up in our client’s list for our sheer dedication towards projects.
OUR SERVICES
DEVELOPMENT
Website Design
CRM
ERP
Job Portal
School Portal
Hospital Portal
Corporate
Community portal
Real Estate
Entertainment
Matrimony
Tour & Travels
Resort Booking
E COMMERCE
Textiles Shop
Pharmacy
Furniture
Gift Shop
Accessories
Jewellery
Fruits Shop
Sea Foods
Restaurant
Book Shop
Electrical
Tools Shop
Foot Wear
MARKETING
SEO
SMM
SEM
SMO
ERP
Branding
IOS AND ANDROID APPS
Pharmacy
Electrical
Gift Shop
Accessories
Jewellery
Textiles Shop
Fruits Shop
Tools Shop
Sea Foods
Restaurant
Furniture
Book Shop
Foot Wear
BEST DEVELOPMENT COMPANY IN CHENNAI
Business Process Management
BPM on Apple Infoway Pvt Ltd is a daily job by any employee on premises. BPM is supervising and considering the processes present in an organization. BPM technique is tried in tragic situation to make sure mechanism is dynamic & adequate, that results in admirable and more cost effective organization
Customer Relation Management
CRM on Apple Infoway Pvt Ltd is a daily job by any employee on premises. Software which stores and manages all the records related to old and current customers at a centralized location within the company and can be accessed anywhere from the company’s offices. CRM Software helps in streamlining the Sales, Marketing, Customer Service and Support divisions of the companies.
Enterprise Resource Planning
ERP on Apple Infoway Pvt Ltd is a daily job by any employee on premises. An integrated system used by organizations to combine, organize and maintain the data necessary for operations. When these tasks are done without focus and solid planning, the ERP software project can have severe repercussions that negatively affect the organization for many years to come
Digital Marketing
Digital Marketing on Apple Infoway Pvt Ltd is a daily job by any employee on premises. Our strategy or planning for the most effective exposure of your products and services would be difference. The popularity of Gadgets like Smartphone’s, Computers, Digital Media's, Internet and online shopping is the reason for growth
Job Portal
Job Portal on Apple Infoway Pvt Ltd is a daily job by any employee on premises. A system containing Web events which provides enrichment and features so as to confirm, resolve and identify the candidate using it. Portal Development successfully provides the user expectable, customized, user friendly and security. Personalized interface on the Web for facilitating and providing an easy access to services and information
Web Design & Development
Web Design & Development on Apple Infoway Pvt Ltd is a daily job by any employee on premises. The one of the creative and unique professional web design company. We have a unique creative team to produce tons of unique designs where you can’t get from any web design companies that's also a reason for why clients prefer us. Our skilled & expert developers have successfully developed many web projects i.e. develops Static Websites, dynamic Websites, Web Portals, etc
Search Engine Optimization
Search Engine Optimization on Apple Infoway Pvt Ltd is a daily job by any employee on premises. In quality wise we offers best service by providing complete knowledge on onpage and offpage seo optimization techniques, and we takes short time to complete our client projects since we have an huge number of people those who works for SEO.
Social Media Optimization
Social Media Optimization on Apple Infoway Pvt Ltd is a daily job by any employee on premises. Using number of outlets and communities to generate publicity to increase the awareness of a product, service brand or event. Types of social media involved include RSS feeds, social news and bookmarking sites.
Search Engine Marketing
Search Engine Marketing on Apple Infoway Pvt Ltd is a daily job by any employee on premises. A form of Internet marketing that involves the promotion of websites by increasing their visibility in search engine results pages (SERPs) primarily through paid advertising.
Social Media Marketing
Social Media Marketing on Apple Infoway Pvt Ltd is a daily job by any employee on premises. Using the social media platforms and websites to promote a product or service. Although the terms e-marketing and digital marketing are still dominant in academia, social media marketing is becoming more popular for both practitioners and researchers.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO:+91 - 93800 37777 ,+91 - 90873 22777 ,+91 - 89399 95548
WEBSITE: [email protected]
0 notes
Text
Trastuzumab Herceptin 440mg - Anticancer drugs | Roche | MHP
HERCEPTIN
DESCRIPTION
Herceptin 440mg injection be expressed by a targeted cancer drug known as Trastuzumab, which is Pharmacologically classify as humanized monoclonal antibody produced by recombinant DNA technology.Herceptin 440mg helps to decrease the rate of reactivation & mortality. One of the epidermal growth factor receptor is known as human epidermal growth factor receptor 2 (HER2) plays vital role in breast cancer.
This factor is responsible for cell replication. An FDA approved product Herceptin which is involved in breast cancer treatment.Herceptin 440mg vial with 858mg of lyophilized powder containing 440mg of Trastuzumab
INDICATION
The drug Herceptin 440mg is used for the treatment of Supportive treatment for breast cancer The drug Herceptin is used for the treatment of Advanced breast cancer The drug Herceptin 440mg is used for the treatment of Advanced gastric cancer
MECHANISM
Herceptin 440mg injection is a type of monoclonal antibody which targeting the HER2, provoke a resistant mediate reaction which causes disguise and down regulation of HER2. HER2 pathway is specific for cell proliferation, joining of Transtuzumab to the site of HER2 causes prevention of this activity. This joining leads to antibody mediated and leads to HER2 positive cells break down. Herceptin 440mg injection is a intermediary of anti-body dependent cellular cytotoxicity. Distribution: Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab emtansine. Metabolism: As trastuzumab emtansine: which Undergoes deconjugation and catabolism through proteolysis in cellular lysosomes. Excretion: Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly regimen); approx 4 days as trastuzumab emtansine. Elimination of drug includes clearance of IgG through the reticuloendothelial system.
PRODUCT DETAILS
Brand : Herceptin
Ingredients : Trastuzumab
Strength : 440mg
Manufactured :Roche
Package :two vials in a carton, one vial containing drug Transtuzumab & one vial containing bacteriostatic water
DOSAGE MANAGEMENT
Adjuvant regimen for HER2 over expressing Breast cancer:
52 weeks of treatment total schedules as follows: Combination With paclitaxel or docetaxel ,over a 90 minutes, 4mg/kg IV then over 30 minutes , 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel for 18 weeks one week following the last weekly dose. Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
ESOPHAGEAL CARCINOMA OR GASTRIC CANCER FOR ADULT DOSE:
8mg/kg IV over 90 minutes as initial dose 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose Duration of therapy for initial and maintenance dose until disease progression.
BREAST CANCER METASTATIC HER2-OVEREXPRESSING:
Over a 90 minutes, 4mg/kg alone or with combination of paclitaxel in initial dose. Over 30 minutes, 2mg /kg once in a week for maintenance dose. Duration of therapy for initial and maintenance dose until disease progression.
ADMINISTRATION
Herceptin 440mg injection is administer into vein through IV infusion over 90 minutes Do not administer IV push or bolus. Duration of Herceptin 440mg is administrated in once every week or every 3 weeks. Before starting treatment, patients should undergo biopsy to check Herceptin 440mg injection is the right regimen The infusion solution should be compatible to polyvinyl chloride or polyethylene bags. After dilution, the infusion bag should be stored at 2oC to 8oC for not more than 24 hours before use.
SAFETY MEASURES
EMBRYO FETAL DAMAGE
Herceptin 440mg injection is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment
CARDIOMYOPATHY
Herceptin 440mg receiving patients have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinue
PULMONARY TOXICITY
Some serious fatal cases of pulmonary toxicity occur during Herceptin 440mg treatment.
INFUSION REACTIONS
During Herceptin 440mg injection treatment some life threatening infusion reactions are produced. In serious infusion reactions, Stop the Herceptin 440mg treatment permanently. Patient should be treated with premedication before starting the infusion to overcome the such problem, During Herceptin 440mg treatment.use with Caution.
THERAPY INDUCED NEUTROPENIA
Higher incidence of neutropenia occurs during Herceptin 440mg treatment.
SIDE EFFECTS
THE MOST COMMON ADVERSE EFFECTS
Cardiomyopathy
Infusion reactions
Embryo fetal toxicity
Pulmonary toxicity
Chemotherapy induced neutropenia
THE MOST COMMON SIDE EFFECTS
Hypertension
Influenza
Dyspnae
URI
Rhinitis
Pharyngolaryngeal pain
Sinusitis
Epitasis
Pulmonary hypertension
Dizziness
Decrease LVEF
Palpitations
Arrhythmia
Cardiac failure
Cough
Interstitial pneumonitis
Diarrhea/constipation
Nausea, vomiting
Dyspepsia
Autoimmune thyroiditis
Neutropenia
Hypokalemia
Anemia
Thrombocytopenia
Febrile neutropenia
Renal failure
Abdominal pain
Arthralgia
Back pain
Bone pain
Headache
Paresthesia
1Rash
Nail disorders
Pruritus
Pyrexia
Chills
Edema
Asthenia
Sudden death
PREGNANCY:
Herceptin 440mg injection pregnancy category is D: Herceptin 440mg should not suggest during pregnancy condition. Breast feeding should not be recommended.
STORAGE :
Herceptin 440mg vials should be stored at refrigerator temperature of 2°C to 8°C Keep the vial away from heat & light After reconstitution, vial should be stored at 2°C to 8°C for 28 days. Stored Herceptin 440mg injection diluted bag at 2°C to 8°C for 24 hours
MISSED DOSE:
If missed cycles of Herceptin 440mg treatment by one week or less, then the repeated maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedule: 6mg/kg) administer as soon as probably. Until the next planned cycle the patient does not take interval. Consecutive Herceptin 440mg injection maintenance dose should be taken in 7 days or 21 days next confer to the weekly or 3 weekly schedules. If patient missed to take Herceptin 440mg dose by higher than one week, then resume with re-storing dose of Herceptin 440mg injection such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should be administered over period of 90 minutes.
CONTACT DETAILS
EMAIL: [email protected]
PHONE NO: +91-9940472902
WEBSITE: https://millionpharma.com/herceptin.php
0 notes